Global Information
회사소개 | 문의 | 비교리스트

세계의 RWE(Real World Evidence) 솔루션 시장

Real World Evidence Solutions

리서치사 Global Industry Analysts, Inc.
발행일 2021년 04월 상품코드 958534
페이지 정보 영문 181 Pages 배송안내 1-2일 (영업일 기준)
가격
US $ 4,950 ₩ 6,444,000 PDF (Single User License)
US $ 14,850 ₩ 19,334,000 PDF (Global License to Company and its Fully-owned Subsidiaries)


세계의 RWE(Real World Evidence) 솔루션 시장 Real World Evidence Solutions
발행일 : 2021년 04월 페이지 정보 : 영문 181 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계 RWE(Real World Evidence) 솔루션 시장 규모는 분석기간(2020년-2027년)에 13.7%의 연평균 복합 성장률(CAGR)로 성장할 전망이며, 2020년 7억 7,080만 달러에서 2027년에는 19억 달러에 달할 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 데이터 세트는 분석기간 중 14.3%의 CAGR을 나타내고, 13억 달러에 달할 전망입니다.

세계의 RWE(Real World Evidence) 솔루션 시장에 대해 조사했으며, 시장 점유율, 동향 및 전망, 성장요인, 지역별 시장 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

조사 대상 기업 예

  • Anthem, Inc.
  • Clinigen Group Plc
  • Cognizant Technology Solutions Corporation
  • IBM Corporation
  • ICON PLC
  • IQVIA
  • Optum, Inc.
  • Oracle Corporation
  • Parexel International Corporation
  • PerkinElmer, Inc.
  • Pharmaceutical Product Development LLC
  • SAS Institute, Inc.
  • Syneos Health

목차

I. 서론, 조사 방법, 조사 범위

II. 개요

  • 시장 개요
    • 코로나19(COVID-19)의 영향과 다가오는 세계 경기침체
    • 경쟁사의 시장 점유율
    • 경쟁사의 시장 점유율 시나리오
  • 주요 기업
  • 동향과 성장요인
  • 세계 시장 전망

III. 시장 분석

  • 지역별 시장 분석
  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 기타 지역

IV. 경쟁

  • 기업 프로파일 : 41개사
LSH 20.10.05

Abstract:

Global Real World Evidence Solutions Market to Reach $1.9 Billion by 2027

Amid the COVID-19 crisis, the global market for Real World Evidence Solutions estimated at US$770.8 Million in the year 2020, is projected to reach a revised size of US$1.9 Billion by 2027, growing at aCAGR of 13.7% over the period 2020-2027. Data Sets, one of the segments analyzed in the report, is projected to record 14.3% CAGR and reach US$1.3 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Services segment is readjusted to a revised 12.4% CAGR for the next 7-year period.

The U.S. Market is Estimated at $227.8 Million, While China is Forecast to Grow at 13.2% CAGR

The Real World Evidence Solutions market in the U.S. is estimated at US$227.8 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$329.8 Million by the year 2027 trailing a CAGR of 13.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 12.2% and 11.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 10% CAGR.

Select Competitors (Total 46 Featured) -

  • Anthem, Inc.
  • Clinigen Group Plc
  • Cognizant Technology Solutions Corporation
  • IBM Corporation
  • ICON PLC
  • IQVIA
  • Optum, Inc.
  • Oracle Corporation
  • Parexel International Corporation
  • PerkinElmer, Inc.
  • Pharmaceutical Product Development LLC
  • SAS Institute, Inc.
  • Syneos Health

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Real World Evidence Solutions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Real World Evidence Solutions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 3: World 15-Year Perspective for Real World Evidence Solutions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2018 & 2027
    • TABLE 4: World Current & Future Analysis for Data Sets by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Data Sets by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 6: World 15-Year Perspective for Data Sets by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027
    • TABLE 7: World Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 9: World 15-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027
    • TABLE 10: World Current & Future Analysis for Pharmaceutical & Medical Device Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Pharmaceutical & Medical Device Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 12: World 15-Year Perspective for Pharmaceutical & Medical Device Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027
    • TABLE 13: World Current & Future Analysis for Healthcare Payers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Healthcare Payers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 15: World 15-Year Perspective for Healthcare Payers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027
    • TABLE 16: World Current & Future Analysis for Healthcare Providers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Healthcare Providers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 18: World 15-Year Perspective for Healthcare Providers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027
    • TABLE 19: World Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 21: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 22: USA Current & Future Analysis for Real World Evidence Solutions by Component - Data Sets and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 23: USA Historic Review for Real World Evidence Solutions by Component - Data Sets and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 24: USA 15-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Data Sets and Services for the Years 2012, 2018 & 2027
    • TABLE 25: USA Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Device Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 26: USA Historic Review for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Device Companies, Healthcare Payers, Healthcare Providers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 27: USA 15-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Device Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2012, 2018 & 2027
  • CANADA
    • TABLE 28: Canada Current & Future Analysis for Real World Evidence Solutions by Component - Data Sets and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 29: Canada Historic Review for Real World Evidence Solutions by Component - Data Sets and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 30: Canada 15-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Data Sets and Services for the Years 2012, 2018 & 2027
    • TABLE 31: Canada Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Device Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 32: Canada Historic Review for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Device Companies, Healthcare Payers, Healthcare Providers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 33: Canada 15-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Device Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2012, 2018 & 2027
  • JAPAN
    • TABLE 34: Japan Current & Future Analysis for Real World Evidence Solutions by Component - Data Sets and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 35: Japan Historic Review for Real World Evidence Solutions by Component - Data Sets and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 36: Japan 15-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Data Sets and Services for the Years 2012, 2018 & 2027
    • TABLE 37: Japan Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Device Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 38: Japan Historic Review for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Device Companies, Healthcare Payers, Healthcare Providers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 39: Japan 15-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Device Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2012, 2018 & 2027
  • CHINA
    • TABLE 40: China Current & Future Analysis for Real World Evidence Solutions by Component - Data Sets and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 41: China Historic Review for Real World Evidence Solutions by Component - Data Sets and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 42: China 15-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Data Sets and Services for the Years 2012, 2018 & 2027
    • TABLE 43: China Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Device Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 44: China Historic Review for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Device Companies, Healthcare Payers, Healthcare Providers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 45: China 15-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Device Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2012, 2018 & 2027
  • EUROPE
    • TABLE 46: Europe Current & Future Analysis for Real World Evidence Solutions by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
    • TABLE 47: Europe Historic Review for Real World Evidence Solutions by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 48: Europe 15-Year Perspective for Real World Evidence Solutions by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2018 & 2027
    • TABLE 49: Europe Current & Future Analysis for Real World Evidence Solutions by Component - Data Sets and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 50: Europe Historic Review for Real World Evidence Solutions by Component - Data Sets and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 51: Europe 15-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Data Sets and Services for the Years 2012, 2018 & 2027
    • TABLE 52: Europe Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Device Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 53: Europe Historic Review for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Device Companies, Healthcare Payers, Healthcare Providers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 54: Europe 15-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Device Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2012, 2018 & 2027
  • FRANCE
    • TABLE 55: France Current & Future Analysis for Real World Evidence Solutions by Component - Data Sets and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 56: France Historic Review for Real World Evidence Solutions by Component - Data Sets and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 57: France 15-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Data Sets and Services for the Years 2012, 2018 & 2027
    • TABLE 58: France Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Device Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 59: France Historic Review for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Device Companies, Healthcare Payers, Healthcare Providers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 60: France 15-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Device Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2012, 2018 & 2027
  • GERMANY
    • TABLE 61: Germany Current & Future Analysis for Real World Evidence Solutions by Component - Data Sets and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 62: Germany Historic Review for Real World Evidence Solutions by Component - Data Sets and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 63: Germany 15-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Data Sets and Services for the Years 2012, 2018 & 2027
    • TABLE 64: Germany Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Device Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 65: Germany Historic Review for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Device Companies, Healthcare Payers, Healthcare Providers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 66: Germany 15-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Device Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2012, 2018 & 2027
  • ITALY
    • TABLE 67: Italy Current & Future Analysis for Real World Evidence Solutions by Component - Data Sets and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 68: Italy Historic Review for Real World Evidence Solutions by Component - Data Sets and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 69: Italy 15-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Data Sets and Services for the Years 2012, 2018 & 2027
    • TABLE 70: Italy Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Device Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 71: Italy Historic Review for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Device Companies, Healthcare Payers, Healthcare Providers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 72: Italy 15-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Device Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2012, 2018 & 2027
  • UNITED KINGDOM
    • TABLE 73: UK Current & Future Analysis for Real World Evidence Solutions by Component - Data Sets and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 74: UK Historic Review for Real World Evidence Solutions by Component - Data Sets and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 75: UK 15-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Data Sets and Services for the Years 2012, 2018 & 2027
    • TABLE 76: UK Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Device Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 77: UK Historic Review for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Device Companies, Healthcare Payers, Healthcare Providers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 78: UK 15-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Device Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2012, 2018 & 2027
  • REST OF EUROPE
    • TABLE 79: Rest of Europe Current & Future Analysis for Real World Evidence Solutions by Component - Data Sets and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 80: Rest of Europe Historic Review for Real World Evidence Solutions by Component - Data Sets and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 81: Rest of Europe 15-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Data Sets and Services for the Years 2012, 2018 & 2027
    • TABLE 82: Rest of Europe Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Device Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 83: Rest of Europe Historic Review for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Device Companies, Healthcare Payers, Healthcare Providers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 84: Rest of Europe 15-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Device Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2012, 2018 & 2027
  • ASIA-PACIFIC
    • TABLE 85: Asia-Pacific Current & Future Analysis for Real World Evidence Solutions by Component - Data Sets and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 86: Asia-Pacific Historic Review for Real World Evidence Solutions by Component - Data Sets and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 87: Asia-Pacific 15-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Data Sets and Services for the Years 2012, 2018 & 2027
    • TABLE 88: Asia-Pacific Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Device Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 89: Asia-Pacific Historic Review for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Device Companies, Healthcare Payers, Healthcare Providers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 90: Asia-Pacific 15-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Device Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2012, 2018 & 2027
  • REST OF WORLD
    • TABLE 91: Rest of World Current & Future Analysis for Real World Evidence Solutions by Component - Data Sets and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 92: Rest of World Historic Review for Real World Evidence Solutions by Component - Data Sets and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 93: Rest of World 15-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Data Sets and Services for the Years 2012, 2018 & 2027
    • TABLE 94: Rest of World Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Device Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 95: Rest of World Historic Review for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Device Companies, Healthcare Payers, Healthcare Providers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 96: Rest of World 15-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Device Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2012, 2018 & 2027

IV. COMPETITION

  • Total Companies Profiled: 46
Back to Top
전화 문의
F A Q